SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-115226
Filing Date
2023-11-07
Accepted
2023-11-07 16:05:42
Documents
14
Period of Report
2023-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2330006d1_8k.htm   iXBRL 8-K 25565
2 EXHIBIT 99.1 tm2330006d1_ex99-1.htm EX-99.1 82312
6 GRAPHIC image_001.jpg GRAPHIC 7707
  Complete submission text file 0001104659-23-115226.txt   305953

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA iova-20251107.xsd EX-101.SCH 3003
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE iova-20251107_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE iova-20251107_pre.xml EX-101.PRE 22351
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2330006d1_8k_htm.xml XML 3334
Mailing Address 825 INDUSTRIAL ROAD 4TH FLOOR SAN CARLOS CA 94070
Business Address 825 INDUSTRIAL ROAD 4TH FLOOR SAN CARLOS CA 94070 6502607120
IOVANCE BIOTHERAPEUTICS, INC. (Filer) CIK: 0001425205 (see all company filings)

IRS No.: 753254381 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36860 | Film No.: 231383661
SIC: 2836 Biological Products, (No Diagnostic Substances)